Quantcast
Last updated on April 23, 2014 at 12:54 EDT

Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer

August 2, 2012

BLAUVELT, N.Y., Aug. 2, 2012 /PRNewswire-iReach/ — A study published in the International Journal of Gynecological Cancer shows that fermented wheat germ extract (FWGE) is effective in killing a wide range of ovarian cancer cells while simultaneously enhancing the cancer-fighting qualities of certain chemotherapy treatments. Previous human clinical studies with FWGE have shown it can significantly improve survival in melanoma, colorectal and oral cancer patients and lessen the side effects of chemotherapy in pediatric cancer patients.

Lead author of the study is Patricia Judson, MD, gynecologic oncologist and researcher at Moffitt Cancer Center in Tampa, Florida’s only National Cancer Institute-designated comprehensive cancer center. Having published more than 40 research articles that have examined standards of cancer treatments including radiation and chemotherapy, Judson says she is most excited about the promise fermented wheat germ extract has shown.

“The results of this study greatly exceeded my expectations,” said Dr. Judson. “We have proven that Avemar (FWGE) has the ability to kill cancer cells in the petri dish, and that it enhances the effectiveness of chemotherapy treatments.” Judson expressed gratitude to the Moffitt Cancer Center Merit Society for funding this study, and said she is actively seeking grants to underwrite the next stage in Avemar research, which will be ovarian cancer trials in animals and ultimately humans.

The study, which had 13 contributors, reinforces and expands upon prior published research that has shown the potential of fermented wheat germ extract as a non-toxic, cancer-fighting agent. According to the study, the team’s findings “confirm the value of Avemar – fermented wheat germ extract (FWGE) – as a natural product with anticancer properties that also enhances the activity of existing therapeutic agents. Furthermore, our findings provide substantial insights into the molecular basis of FWGE’s effect on human cancer cells.”

FWGE was invented by Hungarian biochemist Mate Hidvegi, Ph.D., and has been the subject of more than 100 international experiments on three continents, and more than 30 peer-reviewed articles. Since inventing this all-natural nutraceutical in the early 1990s, Hidvegi has worked to advance the therapeutic potential for patients diagnosed with a variety of cancers. Previous human clinical studies with Avemar have shown it can significantly improve survival in melanoma, colorectal and oral cancer patients and can lessen the side effects of chemotherapy in pediatric cancer patients.

The patented product is manufactured by American BioSciences, Blauvelt, NY. Further research and drug development on fermented wheat germ extract is sponsored by MSC BioTarget, a New York-based biotech firm. If you are interested in interviewing the principals and learning more about this research, please contact Rick Jahnke, MSC BioTarget LLC, ph: 201-788-4963, email: rjahnkemscbio@gmail.com

CONTACT: Rick Jahnke, MSC BioTarget LLC
Email: rjahnkemscbio@gmail.com
Phone: (201) 788-4963

Media Contact: Rick Jahnke MSC BioTarget LLC, 201-788-4963, rjahnkemscbio@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE MSC BioTarget LLC


Source: PR Newswire